Navigation Links
Delcath Systems, Inc. Hosts Symposium on Chemosaturation at CIRSE Annual Meeting
Date:9/14/2011

se to the positive Phase 2 data in neuroendocrine tumors presented earlier this week—is evidence of growing interest in chemosaturation among physicians in Europe."

About Delcath SystemsDelcath Systems, Inc. is a development stage specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Hepatic CHEMOSAT delivery system in April 2011. The Company has not yet received FDA approval for commercial sale of its system in the United States. For more information, please visit the Company's website at http://www.delcath.com/.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver including neuroendocrine tumors, acceptability of the Phas
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Announces Top-Line Results From Metastatic Colorectal Cohort in Phase II Trial of Chemosaturation System
2. Delcath Announces Encouraging Top-Line Results From Hepatobiliary Cohort in Phase II Trial of Chemosaturation System
3. Delcath to Present at the Wedbush 2011 Life Sciences Conference on August 16, 2011
4. Delcath Systems to Report Second Quarter Progress Update and Conduct Conference Call
5. Delcath Systems, Inc. Announces the Completion of Common Stock Offering
6. Delcath Systems, Inc. Announces the Sale of 5,000,000 Shares of Common Stock
7. Delcath on Preliminary List of Additions to Russell Microcap® Index
8. Delcath to Present at the JMP Securities Research Conference
9. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
10. Delcath Receives Notice of European Regulatory Approval for Hepatic CHEMOSAT™ Delivery System
11. Delcath to Update Investors on FDA Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... application process, CSA Medical, Inc. ( www.CSAmedical.com ) has ... future plans for its proprietary spray cryotherapy platform on ... will take place from 10:20-10:50 am at the Walter ... CSA Medical is first to harness the power of ...
... EMERYVILLE, Calif., Oct. 7 Onyx Pharmaceuticals, Inc. (Nasdaq: ... teleconference to provide a status update on its New Drug ... webcast of the presentation on our website at: ... 847-585-4405 and using the passcode 28119641. A replay of the ...
Cached Medicine Technology:CSA Medical Selected to Present at AdvaMed 2010: The MedTech Conference 2Onyx Pharmaceuticals Announces Teleconference to Provide Status Update on Carfilzomib 2
(Date:4/23/2014)... and Leisure Time Physical Activity on Mobility Limitation in ... increases the risk of mobility limitation in old age, ... found in a study which followed up 5,200 public ... at the Gerontology Research Center in Finland and the ... is often repetitive, wears the body and lasts for ...
(Date:4/23/2014)... as Ritalin, may prevent the depletion of self-control, according ... journal of the Association for Psychological Science. , Self-control ... trying to focus attention on a boring textbook are ... explanation for this difficulty: Exerting self-control for a long ... effectively on subsequent tasks. , "It is as if ...
(Date:4/23/2014)... the bottom of Alzheimer,s disease has been a ... controversies. In the latest crook in the research ... the interaction between proteins associated with the disease. ... ACS Chemical Neuroscience , could have important implications ... Krzysztof Nieznanski and colleagues explain that for years, ...
(Date:4/22/2014)... and industry leaders visited the New Jersey Institute ... Joel S. Bloom for the launch of the ... that provides a new model for business innovation ... education assets and investment. U.S. Senator Cory Booker, ... Joe Taylor, New Jersey Lieutenant Governor Kim Guadagno, ...
(Date:4/22/2014)... the last few decades researchers have characterized a set ... and behavior in all types of species, from flies ... identified, but researchers surmise there are more. A team ... of Pennsylvania wondered if big-data approaches could find them. ... by John Hogenesch, PhD, professor of Pharmacology and first ...
Breaking Medicine News(10 mins):Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:ADHD drug may help preserve our self-control resources 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2
... a Million People Nationwide to take 10 Billion, Steps ... WASHINGTON, Sept. 17 More than 1,500 YMCAs ... active living and,healthy eating during "America On the Move ... partnership with the America On the Move,Foundation, aims to ...
... Science Series to Focus on Cardiovascular Disease, Prevention and Treatment Options, ... ... NEW YORK, Sept. 17 The upcoming episode of the "Charlie,Rose ... leading,global killers, which claims almost 900,000 lives each year in the United,States ...
... A new study by researchers at the University of Southern ... , Researchers found that a storyline on the primetime ... and healthy eating habits had a positive impact on the ... study, published in the Sept. 14 Journal of Health Communication ...
... cancer in the head and neck region may have ... without the disease, according to a report in the ... one of the JAMA/Archives journals. , Driving is a ... functions that work together. These functions can be compromised ...
... the Medicare,Quality Improvement Organization for Florida, is ... Laredo, Texas to provide free Diabetes,Empowerment Education ... 33,Florida counties. According to Kathleen Lightbourne, Project ... "The Program is designed to help,people with ...
... Open House - Saturday, October 20,Event to be held ... WEST PLAINS, Mo., Sept. 17 GAMMILL QUILTING ... systems, in,cooperation with it,s nationwide network of dealers, will ... 20. This event is being,held in honor of October,s ...
Cached Medicine News:Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 2Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 3Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 4Health News:Activate America(R) Brings Together YMCAs Nationwide to Promote Small Steps Toward a Healthier Lifestyle During 'America on the Move Week With the YMCA,' September 22-29, 2007 5Health News:Charlie Rose Science Series Explores Heart Disease 2Health News:Charlie Rose Science Series Explores Heart Disease 3Health News:ER episode impacts viewers' health knowledge and behavior 2Health News:Patients with head and neck cancer may have impairment of some driving skills 2Health News:Medicare Every Diabetic Counts Project Gears Up for Kick-Off 2Health News:'Think Pink with Gammill(R)' 2
... The ACS:180 SE is a ... PLUS, consisting of important physical ... simplify routine operation and increase ... the "Next Generation" ACS:180. The ...
... wide range of Platelet aggregometers allows ... meet particular needs. Single, dual and ... chart recorder outputs or digital computer ... Optical aggregometers, which measure platelet aggregation ...
... you in achieving improved cost efficiency ... to cut costs is constantly increasing. ... eliminate unnecessary manual interactions. Ensuring security ... control mechanisms like pipetting integrity check. ...
... Advia 2400 has minimal ... (as low as 2 ... (40 L/hour) thus maximizing ... universal rack handler facilitates ...
Medicine Products: